Search
Gadofosveset trisodium
go.drugbank.com/drugs/DB06705ApprovedGadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. I...
Ifenprodil
go.drugbank.com/drugs/DB08954ApprovedInvestigationalWithdrawn] it has also been shown to have an immunomodulatory effect. … [A220133] Further studies elucidated that ifenprodil binds strongly at the inter-subunit interface of adjacent GluN1 and GluN2B NTDs, where it acts as a non-competitive antagonist.
Vanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigational[L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor
Tagatose
go.drugbank.com/drugs/DB04936InvestigationalIt is approved as a food additive as a low calorie sweetener. Additionally, it is under investigation by Spherix for the treatment of obesity and type II diabetes.
Clothiapine
go.drugbank.com/drugs/DB13256ApprovedClothiapine has been approved in European countries and is an atypical antipsychotic, shown to be useful in some treatment-resistant patients.
R-30490
go.drugbank.com/drugs/DB09179ExperimentalIt was first synthesized by Janssen Pharmaceutica as part of a structure-activity relationship study of fentanly and its derivatives. … R-30490 is an opioid related to carfentanil used as an animal tranquilizer.
ACA 125
go.drugbank.com/drugs/DB05489InvestigationalTo create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. Positive clinical results are now being reported. … An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies.
Elacridar
go.drugbank.com/drugs/DB04881InvestigationalAs of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have been discontinued.
Odanacatib
go.drugbank.com/drugs/DB06670InvestigationalOdanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].
Reproterol
go.drugbank.com/drugs/DB12846InvestigationalReproterol has been used in trials studying the treatment of Asthma, Exercise-Induced.